Objective In dual-time-point PET/CT, early delayed scanning (D-1) just after the completion of whole body scanning (E) is easy to perform without additional radiation exposure and repositioning. Our aim was to assess the clinical value of D-1 compared with conventional delayed scanning (D-2). Methods Our institutional review board approved this retrospective study. Fifty-four patients with known or suspected colorectal cancer underwent 18 F-FDG PET/CT at our institution. The E scan at 1-h post-injection was followed by D-1 at 85 ± 7 min post-injection and D-2 at 124 ± 7 min post-injection. The clinical value of D-1 was evaluated by comparing diagnostic performance with D-2 for differentiating physiologic from pathological uptake and for staging colorectal cancer. Colonoscopic findings, histopathological results and clinical follow-up including radiological findings were used as reference standards. Results Thirty-two, eight and 73 focal or short segmental FDG foci by physiologic processes in the colon/rectum, the small intestine and the ureter, respectively, noted in the E scan were evaluated in this study. Using D-1 and D-2, 14/32 (44 %) and 17/32 (53 %) in the colon/rectum, 5/8 (63 %) and 8/8 (100 %) in the small intestine, and 55/73 (75 %) and 69/73 (95 %) in the ureter, respectively, were accurately interpreted as physiologic with the change of intensity and/or shape/location. A significant difference between D-1 and D-2 was observed in the ureter, but not in the bowel. The 55 colorectal cancers were finally diagnosed in 52 patients. In the staging of colorectal cancer, there were no significant differences among the three scans in the lesion-based detectability, the patient-based sensitivity, specificity and accuracy for the identification of primary tumors, nodal and hepatic metastases, and dissemination. Conclusions Neither D-1 nor D-2 improved staging of colorectal cancer. However, delayed scans yielded information useful for differentiating physiologic uptake from pathological uptake and D-1 may provide comparable efficacy with D-2 in the bowel. Because of the ease of acquisition, the D-1 scan was considered a practical way to reduce false-positives in the abdomen and possibly helpful to avoid unnecessary additional invasive examinations, such as colonoscopy.
Introduction
In oncological PET or PET/CT studies, dual-time-point scanning may be helpful in establishing a correct diagnosis. Previous reports have shown that malignant lesions often show a gradual increase of FDG accumulation from an early phase to a delayed phase, and that dual-time-point PET or PET/CT studies provide increased ability to detect malignant lesions or facilitate the differentiation of malignant lesions from benign lesions [1] [2] [3] [4] [5] [6] [7] . At our institute, additional data acquisition with delayed scanning has been performed when it is considered helpful in differentiating between physiologic uptake and pathological uptake observed in the first emission scan (early scan, E scan), especially in the abdomen. However, the conventional delayed scan approach (D-2 scan) has some drawbacks.
Generally, it is performed 2-3 h after injection of FDG, and necessitates a repositioning of patients. The extension of the study time and additional radiation exposure with CT in the case of PET/CT may give cause to hesitate when applying this procedure in a clinical setting.
The advances of a PET/CT device have enabled additional emission scanning just after the first emission scanning (E scan). This so-called early delayed scanning (D-1 scan) is easy to perform in the clinical setting, requiring only another 10 min for scanning of the whole abdomen, without repositioning of patients nor additional radiation exposure by CT. However, it remains unknown whether the D-1 scan has the same diagnostic efficacy as the conventional delayed scanning (D-2 scan).
The purpose of this study was to investigate the usefulness of dual-time-point PET/CT in patients with known or suspected colorectal cancer, and to assess the clinical value of the D-1 scan, compared with the D-2 scan. Our investigation was focused on the following two aspects: (a) differentiation of physiologic uptake from pathological uptake, and (b) diagnostic performance for the initial staging of colorectal cancer.
Materials and methods

Patients
From September 2009 to February 2011, 71 consecutive patients with known or suspected colorectal cancer who received colonoscopy underwent FDG PET/CT scanning at three time points, i.e. the E, D-1 and D-2 scans, for initial staging at our institute. Excluding patients who had a plasma glucose level greater than 150 mg/dl (n = 4), who had polyposis (n = 1), for whom chemotherapy had begun before PET/CT (n = 2), who received colonoscopy more than 3 months before or after PET/CT (n = 2), whose follow-up period was insufficient for obtaining reference standard (n = 2), and whose scanning range in the delayed scans did not cover the whole abdomen (n = 6), a total of 54 patients (32 men and 22 women, mean age 66 years, age range 20-90 years) were retrospectively analyzed in this investigation. The patients' profiles are summarized in Table 1 . The stage of colorectal cancer was classified based on the American Joint Committee on Cancer (AJCC) TNM staging system, 7th edition [8] . Our institutional review board approved this study, and all patients gave their written informed consent to the PET/CT examinations as well as to the scientific evaluation of the data.
Imaging protocol PET/CT scans were performed using a Discovery ST Elite scanner (GE Healthcare, Waukesha, WI, USA). Patients fasted for at least 4 h prior to the PET/CT study. Patients' plasma glucose level was obtained just before injection of FDG, and ranged from 71 to 143 mg/dl. After intravenous administration of 102-311 MBq of FDG, patients rested in a waiting room. Approximately 1 h later, as demonstrated in Fig. 1 , low-dose CT images were acquired using a 16-detector row scanner with the following parameters: 20-100 mA depending on anatomic location using an automated exposure control system, 120 kV, 0.6 s tube rotation, 3.75 mm section thickness, 512 9 512 matrix, and 1.75:1 pitch factor. The CT scan was acquired during shallow breathing, and covered from the upper thigh to the skull base. Immediately after CT, an early whole body PET emission scan, i.e. the E scan, was performed at 64 ± 7 min postinjection (mean ± SD) with the following parameters: an acquisition time of 2-3 min per bed position, 128 9 128 matrix, 3.27 mm interval, 2 iterations and 14 subsets. The total acquisition time for the CT and the E scan was approximately 15-25 min. Soon after the completion of the E scan, the early delayed emission scanning, i.e. the D-1 scan, for the whole abdomen was performed at 85 ± 7 min post-injection without additional CT scanning and repositioning. After the D-1 scan, patients left the scanning bed and returned to the waiting room. At 124 ± 7 min post-injection, the conventional delayed emission scan, i.e. the D-2 scan, for the whole abdomen was performed after repositioning of patients and additional low-dose CT scanning. The first CT data set was used for attenuation correction for the E and D-1 scans, and the second CT data set was used for the D-2 scan. Images were reconstructed using the 3D iterative reconstruction algorithm called VUE Point Plus.
Image interpretation
The PET/CT images were assessed in consensus by at least two board-certified radiologists/nuclear medicine physicians. With regard to the colon/rectum, small intestine, ureter and liver, a FDG focus was defined as positive when it showed a focal or short segmental pattern and higher intensity than the normal liver parenchyma by visual assessment. In the lymph node and peritoneum, a FDG focus was regarded as target uptake when it showed a nodular focal pattern and higher intensity than the mediastinal blood pool. Abnormal uptake corresponding to irregular-shaped abnormal tissues on CT was also included as target uptake. Certainty of the positivity of target uptake of the lymph nodes and peritoneum was visually interpreted using a 5-point grading scale as follows: 4 = definitely positive; 3 = probably positive; 2 = equivocal; 1 = probably negative; 0 = negative. Uptake with grade 3 or 4 was categorized as positive.
As to physiologic uptake in the colon/rectum, small intestine and ureter, the change of intensity and shape/ location in the D-1 and the D-2 scans, compared with the E scan, was scored using a 3-point scale: 2 = definitely changed, 1 = slightly changed, 0 = not changed. The sum of the scores of the change of intensity and shape/location was calculated for each FDG focus. When the total score was between 2 and 4, the uptake was interpreted as ''changed'', indicating that the delayed scans helped correct differentiation of the false-positive FDG foci observed in the E scan.
For colorectal FDG foci that were persistently positive and remained visually unchanged during the whole three scans, semiquantitative assessment by maximum standard uptake value (SUVmax) was also conducted.
Standard of reference
Findings from colonoscopy were used as a reference standard for colorectal FDG foci in all 54 patients. Total colonoscopy was performed in 31 patients. In the remaining 23 patients, whole colorectal observation was not achieved because of stenosis caused by tumors or insufficient preparation. Therefore, the proximal colorectal FDG foci beyond the range examined by colonoscopy were assessed by findings at surgery and clinical follow-up for more than 6 months. Final diagnosis of the colorectal FDG foci was categorized as malignant lesions (colorectal cancer and lymphoma), premalignant lesions (advanced adenoma and laterally spreading tumor), benign polyps, and physiologic uptake. Advanced adenomas were defined as larger adenomas ([1 cm) or adenomas with appreciable villous tissue or high-grade dysplasia [9] . Physiologic FDG accumulations in the small intestine were confirmed by surgery or clinical follow-up for more than 6 months. Physiologic FDG excretion in the ureter was diagnosed by clinical follow-up for at least 2 months.
Out of 54 patients, 52 patients were histopathologically proven to have primary colorectal cancer on specimens obtained by colonoscopic biopsy or surgical resection, one patient had intestinal lymphoma, and the remaining patient had an appendiceal cystic adenoma with high-grade atypia. Excluding the two cases without colorectal cancers, a total of 52 patients were analyzed for the diagnostic performance of the initial staging of colorectal cancer. Thirtyeight patients underwent surgery without neoadjuvant chemotherapy (NAC), nine patients had surgery after NAC, and the remaining five patients received chemotherapy without surgery. For nodal metastasis and dissemination, histopathologic results by surgical specimens and clinical follow-up, including size change on CT or magnetic resonance imaging (MRI), were used as the reference Fig. 1 Scanning protocol. Just after completion of the conventional whole body scan (E scan), the early delayed scan (D-1 scan) was performed. Then, patients rested in a waiting room for a short period.
At about 2-h post-injection (p.i.), another delayed scan (D-2 scan) was started after repositioning and additional CT scanning for the whole abdomen standards. In detail, among those who received surgical resection, histologically positive nodal or peritoneal lesions in patients treated with or without NAC were regarded as positive, and histologically negative lesions in those treated without NAC were regarded as negative. In histologically negative lesions in those after NAC, lesions which showed remission during the NAC period were regarded as positive, while those which were stable or progressed were regarded as negative. In cases without surgery, lesions which showed progression or remission during chemotherapy were considered positive, while stable lesions were negative. The site of nodal metastasis was categorized as pericolorectal, intermediate of the mesenterium, and proximal of the zonal artery for region-based analysis. For hepatic metastasis, an increase in size on conventional imaging modalities, including CT and MRI, or a decrease in size in cases with chemotherapy was used as the standard references.
Statistical analysis
In the analysis of physiologic uptake, the number of visually changed/unchanged physiologic FDG foci was compared between the D-1 and D-2 scans by the McNemar test. The scores of the change of intensity and those of location/shape were compared between the two delayed scans by the Wilcoxon signed rank test. For colorectal FDG foci that remained visually unchanged during all three phases, SUVmax was compared among the E, D-1 and D-2 scans by the Friedman test, followed by Dunn's test for a comparison of all pairs. In the analysis of staging of colorectal cancer, lesion/region-based detectability, patient-based sensitivity, specificity and accuracy for the identification of primary tumors, nodal metastases, hepatic metastases and peritoneal dissemination were calculated and compared among the three scans by the Cochran Q test as well as between each pair by the McNemar test with a Bonferroni correction.
All analyses were performed using GraphPad Prism version 5 (GraphPad Software, San Diego, CA, USA) and StatMate version 4 (ATMS, Tokyo, Japan). All p values were two-sided, and p \ 0.05 was considered statistically significant. For multiple comparisons with the Bonferroni correction, p \ 0.017 was considered significant.
Results
Differentiation of physiologic uptake from pathological uptake
In the colon/rectum, there were 90 focal or short segmental FDG foci in the E scan. Of these 90 foci, 32 foci (36 %) were proven to be physiologic uptake, 54 (60 %) were malignant lesions (54 colorectal cancers), 2 (2 %) were premalignant lesions (2 advanced adenomas), and 2 (2 %) were benign lesions (2 polyps). Among a total 56 malignant lesions, two lesions, i.e. a Tis colon cancer and a malignant lymphoma, were not recognized as abnormal FDG foci, resulting in false-negatives. The location of 32 colorectal physiologic FDG foci included the cecum in 5, ascending colon in 3, transverse colon in 5, descending colon in 8, sigmoid colon in 2, rectum in 7, anal in 1, and stoma in 1. With the change of intensity and/or shape/location in D-1 and D-2, 14 (44 %) and 17 (53 %) foci of the 32 false-positive foci in the E scan were accurately diagnosed as physiologic, respectively ( Table 2 ; Fig. 2 ). There was no significant difference between the D-1 and D-2 scans (p = 0.248). In contrast, all 58 colorectal pathological FDG foci remained visually unchanged.
In the small intestine, eight foci of physiologic uptake were found in the E scan. Of these eight foci, five (63 %) and eight (100 %) foci were accurately interpreted as physiologic by considering changes in the appearance from the E scan by D-1 and D-2, respectively. There was no significant difference between the two delayed scans (p = 0.248).
In the ureter, of 73 focal or short segmental physiologic foci in the E scan, 55 (75 %) and 69 (95 %) foci changed in D-1 and D-2, respectively. A significant difference was observed between the D-1 and D-2 scans (p \ 0.001) (Fig. 2) .
Physiologic FDG foci in the small intestine and the ureter frequently showed obvious changes of intensity; they tended to diminish or decrease in the delayed phases. In contrast, colorectal physiologic FDG foci often showed almost the same intensity in the delayed scans as in the E scan by visual assessment. Most of them were categorized as score 0 in terms of the change of intensity (Table 2) . Therefore, the visually noticeable change was obtained mainly from the location and the shape of colorectal FDG foci.
In the colon/rectum, there were a total 15 physiologic FDG foci which were persistently positive and remained visually unchanged during the all three scans. In the semiquantitative assessment for these visually unchanged 15 colorectal physiologic foci, median ± quartile of SUVmax in the E, D-1 and D-2 scans was 4.7 ± 1.8, 5.2 ± 2.3 and 6.4 ± 2.0, respectively (p \ 0.001 by the Friedman test) (Fig. 3) . The SUVmax in the D-1 and D-2 scans was significantly higher than that in the E scan by Dunn's test. Such a tendency was similar to those observed in pathological FDG foci associated with malignant lesions.
Diagnostic performance for staging of colorectal cancer
A total of 55 primary colorectal cancers, including 2 Tis, 2 T1 and 51 T2-4 tumors, were finally confirmed in 52 patients. The E, D-1 and D-2 scans could identify all primary tumors, except one ( Table 3 ). The false-negative lesion was a Tis sigmoid cancer, which was an Isp-shaped adenocarcinoma in adenoma of 6 mm in size. The other tumors, which were larger than 10 mm in size, were truepositive. The lesion-based detectability, patient-based sensitivity and accuracy were 98, 100 and 100 % equally in all three scans.
Nodal metastases were observed in 43 regions in 31 patients. The patient-based sensitivity, specificity and accuracy of the E scan for nodal metastasis were 45, 95 and 65 %, respectively, and for the D-1 and D-2 scans was 55, 90, and 69 %, and 58, 90 and 71 %, respectively. In the region-based analysis, the 49 % detectability in the E scan slightly increased to 56 % in D-1, and 58 % in D-2, because more pericolorectal nodal metastases obtained higher FDG accumulation and were able to be pointed out in the delayed phases. Detectability for nodes in the intermediate of the mesenterium and the proximal zonal artery was not improved with the delayed scans. Although the grade of certainty increased in 5 of 43 cases in D-1 and in 7 of 43 in D-2, with higher diagnostic accuracy and detectability for nodal metastasis in later phases, there was no significant difference among the three scans.
There were a total of nine hepatic metastases in three patients. The smallest metastasis of 8 mm in size was falsenegative in all three phases. One hepatic metastasis with an 11 mm diameter was false-negative in the E scan, but turned out to be true-positive in the D-1 and D-2 scans (Fig. 4) . The other lesions greater than 10 mm were truepositive in all phases. In the lesion-based analysis, the detectability in the delayed scans (89 % in both D-1 and D-2) was higher than that in the E scan (78 %), although without statistical significance. The patient-based sensitivity, specificity and accuracy for hepatic metastasis were equally 100 % in all three phases.
There were three patients with peritoneal dissemination. One patient was true-positive, while the remaining two patients with small implants were false-negative in all three phases. The patient-based sensitivity, specificity and (5) a According to the summation of each score, the time course was classified into two categories, changed (2-4) or unchanged (0 or 1) accuracy were 33, 100 and 96 %, respectively, in all phases.
Discussion
Focal or short segmental FDG accumulations in the alimentary tracts could be associated with pathological abnormalities [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In the colon/rectum, 64-84 % of focal FDG foci correspond to some sort of pathological lesions, including colorectal cancers, metastases, adenomas, polyps, abscess, fistulas, and diverticulitis [9] [10] [11] [12] 18] . Malignant or premalignant lesions account for as high as 57-80 % of colorectal focal FDG foci [9] [10] [11] [12] . Thus, when unexpected focal FDG foci are incidentally observed in PET or PET/CT, additional invasive examination, such as colonoscopy, is generally recommended [9] [10] [11] . Conversely, 13-29 % of focal gastrointestinal FDG foci and 36 % of focal colorectal FDG foci are physiologic [10, 16] , which do not require further observation or treatment. If colonoscopy is performed for all patients with such FDG foci, it would be a physical and economic burden. For these reasons, it is considered clinically important to distinguish pathological uptake from physiologic uptake when interpreting PET/CT images, especially when CT reveals no definite morphological changes. Several attempts to identify physiologic uptake in intestine have been made. Based on the hypothesis that FDG accumulates in the intestinal lumen or the muscle wall, various studies to reduce physiologic uptake using purging or laxative agents or muscle-relaxing drugs have been conducted. However, bowel preparation by sennaglycoside solution was proven to be ineffective [19] , and the effect of anticholinergic drugs was rather controversial [20] [21] [22] . Recently, it has been reported that delayed PET/ CT after administration of oral or anal laxative-augmented (magnesium citrate or phosphosoda enema) contrast medium reduced the number of patients with false-positive or equivocal uptake caused by physiologic processes by 91 % (from 81 to 7) [23] . However, this procedure is rather invasive and laborious. The potential effect of a delayed scan without laxative-augmented contrast media has not been assessed.
In our study, the number of physiologic FDG foci observed in the E scan decreased with the D-1 and D-2 scans by 44 and 53 % in the colon/rectum, and by 62 and 100 % in small intestine, respectively. Although these delayed scans appear to be less effective in reducing false-positives than the delayed scan with laxative-augmented contrast material [23] , a relatively large number of the physiologic FDG foci were correctly classified using the D-1 and D-2 scans. The difference in the diagnostic performance between the two delayed images was not significant in the colon/rectum and the small intestine, but D-2 was more helpful for differentiation than D-1 in small intestine in our population. However, since prevalence of inconclusive findings in small intestine is rather low, the additional D-1 scan may be sufficient in clinical. Thus, although further studies with a larger population are required for a definitive conclusion, especially in small intestine, the D-1 scan may provide comparative diagnostic value to the D-2 scan for the differentiation of physiologic FDG foci. Because of its ease of acquisition, the D-1 scan approach is a practical way to reduce abdominal false-positive uptake foci in the bowel, and may help to avoid additional unnecessary invasive studies.
According to previous reports of dual-time-point FDG PET or PET/CT studies, the value of SUVmax significantly increases in many malignant tumors with time after 1-h post-injection, while benign lesions tend to show a decrease or a subtle increase of SUVmax [2-4, 7, 24] . Hence, the time course of SUVmax has been considered a useful metric to differentiate malignant lesions from benign lesions. In our series, malignant lesions, mostly locally advanced colorectal cancers, showed a gradual increase in the value of SUVmax. These results were consistent with previous reports; however, visually unchanged physiologic FDG foci showed a gradual increase in SUVmax, too. Our observation was similar to the results of the study by Toriihara et al. [25] , in which physiologic FDG uptake in the colon significantly increased from the early to the delayed phase. The time course of SUVmax may not contribute to a differentiation of physiologic from malignant pathological uptake in the bowel.
Focal FDG foci due to urinary excretion in the ureter can be mistaken as paraaortic lymphadenopathy or lesions in organs close to the ureter, such as ovary, cervix, pancreatic tail and adrenal grand [15, 17] . Co-registration of PET with anatomical imaging may be useful to avoid misinterpretation; however, it is still difficult to differentiate lesions in proximity to urinary activity, especially in a PET/CT study acquired without an intravenous contrast agent. Other techniques, such as diluting urinary activity with hydration and diuretics, may be helpful, but not so easy to perform [17] . In contrast, additional delayed scanning is a simple option. In our study, the D-1 and the D-2 scans correctly differentiated 75 and 95 % of physiologic urinary FDG foci observed in the E scan, respectively. The D-2 scan was more effective than the D-1 scan, but even the D-1 scan is thought to be useful in most cases.
In the initial staging of colorectal cancer, the ability to detect primary tumors is generally high with a reported sensitivity of 95-100 % in PET and PET/CT [26] [27] [28] , excluding mucinous types [29] , although additional information obtained by PET or PET/CT for T-staging is limited Fig. 4 A 60-year-old man with an 11 mm hepatic metastasis in the S8 segment. Axial FDG PET image in the E scan (a) shows mild uptake, which is difficult to point out (arrow). Axial FDG PET images in the D-1 scan (b) and the D-2 scan (c) show increased FDG accumulation, which can be accurately diagnosed as positive for hepatic metastasis (b, c arrow) [28] . In N staging, sensitivity is low, in the range of 22-37 % in PET and 43 % in PET/CT, while specificity is high, in the range of 80-96 % in both PET and PET/CT [27, 28, 30] . Concerning hepatic metastases, several patient-based studies have shown relatively high sensitivity of 78-100 % and high specificity of 96-100 % in PET [26, [30] [31] [32] , and high sensitivity of 91 % and specificity of 90 % in PET/CT [33] . However, a prospective study has demonstrated a limited level of lesion-based detectability of 65 % in PET [34] . In particular, identification of hepatic metastasis less than 1 cm in diameter is difficult, with a reported detectability of 25 % in PET [35] . Diagnosis of peritoneal dissemination by PET is unreliable [33, 35] . Hence, a novel diagnostic approach has been required mainly to improve the detectability and sensitivity of nodal metastasis, hepatic metastasis, and peritoneal dissemination. However, our study indicated that the delayed scans could not significantly improve diagnostic performance in the initial staging of colorectal cancer. Therefore, the clinical value of delayed scanning, especially the D-1 scan, may contribute to the differentiation of physiologic from pathological uptake in the bowel without added invasive procedures or further examinations.
There are some limitations of our study. First, the number of subject was small especially for the evaluation of small intestinal physiologic uptake, hepatic metastases and peritoneal dissemination. Further evaluations with a larger population are required for a definitive conclusion. Second, there may have been a selection bias, because the patients who received PET/CT as pre-operative staging for colorectal cancer were enrolled in this study. It should be noted that the rate of advanced cancer was higher than usual. Third, the reference standard was heterogeneous, and included histopathological results, clinical follow-up and colonoscopic findings.
In conclusion, diagnostic performance in the initial staging of colorectal cancer was not improved by either the D-1 or the D-2 scan, as compared with the conventional E scanning; however, the delayed scans correctly differentiated relatively large number of the physiologic FDG foci in the E scan in the colon/rectum, small intestine, and ureter. Furthermore, the D-1 scan may provide comparable efficacy with the D-2 scan in the differentiation of physiologic uptake from pathological uptake in the bowel. Because it is easily acquired, the D-1 scan seems to be a practical way of reducing the incidence of false-positives by physiologic uptake and may help to avoid unnecessary invasive examinations, such as colonoscopy.
